A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma

Recruiting

Intervention to Enhance Cognitive Augmentation and Neuroplasticity (I-CAN)

Who can join

Ages 18 and older · All sexes

Full eligibility criteria

Inclusion Criteria:

* Patients \>= 18 years of age
* Diagnosed with relapsed/refractory multiple myeloma (MM) or B-cell non-Hodgkin lymphoma (B-NHL)
* Expected to receive an Food and Drug administration (FDA)-approved CAR-T cellular treatment
* English literacy

Exclusion Criteria:

* Patients expected to live \< 6 months
* Patients with major medical disorder known to affect cognition, such as stroke, encephalitis, traumatic brain injury, brain surgery
* Confirmed Alzheimer disease or other dementia
* Previous central nervous system (CNS) radiation
* Active intrathecal therapy at time of enrollment

About the study

This clinical trial evaluates whether an online cognitive training intervention (Intervention to enhance Cognitive Augmentation and Neuroplasticity \[I-CAN\]), delivered before and after treatment with chimeric antigen receptor T-cell therapy, works to improve cognitive and neurological outcomes in patients with multiple myeloma or B-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or does not respond to treatment (refractory). Cancer treatment can have significant short and long-term side effects, including cognitive and neurological side effects such as impairments in attention, memory, language, and executive function. The I-CAN program is a form of cognitive training. Cognitive training is a therapeutic approach designed to improve and restore cognitive functioning, based on the brain's ability to reorganize and form new neural connections to accomplish tasks. I-CAN provides five core elements necessary for training the brain to create new neural connections including speed of processing, accuracy of processing, adaptivity, generalizability, and engagement. The I-CAN intervention, when delivered before and after therapy, may help reduce the cognitive side effects of treatment in patients with relapsed or refractory multiple myeloma or B-cell non-Hodgkin lymphoma.

What is being tested

Biospecimen Collection (procedure)
Cognitive Intervention (other)
Electronic Health Record Review (other)
Survey Administration (other)

Sponsor: Ohio State University Comprehensive Cancer Center · Participants: 90 · Started: Apr 28, 2026

Contact the study team

The Ohio State University Comprehensive Cancer Center · Phone: 800-293-5066

Official record on ClinicalTrials.gov — NCT07609030

Locations in the U.S.

Ohio	Ohio State University Comprehensive Cancer Center, Columbus

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.